—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Pfizer Inc (PFE) — chart, structure and Closelooknet read

The Closelooknet read

Pfizer discovers, develops, manufactures and sells biopharmaceutical products worldwide, organised into three segments: Biopharma, PC1 and Pfizer Ignite. Its brands cover internal medicine such as Eliquis and Nurtec, vaccines such as Prevnar and Abrysvo, inflammation and immunology treatments such as Xeljanz and Enbrel, rare disease medicines such as Vyndaqel, oncology therapies such as Ibrance and Xtandi, and biosimilars and sterile injectables.

Detail below: the desk's view, the earnings record, peers and the company snapshot; daily prices on the price-history tab. Research diary readings, not advice.

Pick a ticker to load its detail page.

The desk on PFE

What this diary said about Pfizer Inc, what it holds and what would change its view — in its own words, dated. Investment diary, not advice.

What we said

Signals for this name

Every Closelooknet reading that exists for PFE, from the same nightly bakes the boards use. Research diary readings, not advice.

Mentioned on Closelooknet 7 pieces · newest: Daily Pulse, “Rubin surges as vol complex splits and Europe extends gains” (2026-05-22)

Mentioned on Closelooknet

Where PFE appears in the diary — 7 pieces, newest first. Every link is our own writing.

Dailies

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 47/100 · S&P 500 fund at 48, above its 200-day averageEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-11-06
  • Factor regime Defensive rotation — low-vol leading, regime-change watchMomentum against low volatility (SPMO / SPLV): below its 50-day trend, 60th percentile of the window, -22.8% over 20 sessions. Factor regime → 2026-11-06
  • Sovereign pressure Index -1.91 · down 2.45 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-11-06
How it trades on rate days beta 0.53 to TLT · on the worst bond days it moved with the market

How it trades on rate days

How PFE has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.53 — tends to move with bonds for every 1% move in TLT (20+ year Treasuries), Pfizer Inc moved 0.53% on average · correlation 0.23 · higher than 45% of US names
  • Beta, last 3 months 0.85 more rate-sensitive lately than over the year
  • On the 10 worst bond days −0.54% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days +0.82% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Drug Manufacturers - General · US · 8 names with week and year-to-date

Peer group

Drug Manufacturers - General · US

This name carries no Closelooknet score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against PFE on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Pfizer Inc

PFE in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Pfizer discovers, develops, manufactures and sells biopharmaceutical products worldwide, organised into three segments: Biopharma, PC1 and Pfizer Ignite. Its brands cover internal medicine such as Eliquis and Nurtec, vaccines such as Prevnar and Abrysvo, inflammation and immunology treatments such as Xeljanz and Enbrel, rare disease medicines such as Vyndaqel, oncology therapies such as Ibrance and Xtandi, and biosimilars and sterile injectables. It is headquartered in New York and has traded publicly since 1942.
Where it sits in the stack
Pfizer holds no seat in Rubin, the diary's AI build-out index, and sits outside that stack. In our wider universe it belongs to the healthcare sleeve, under drug manufacturing, alongside other large diversified pharmaceutical companies.
Who it is priced against
The diary records no formal peer group for Pfizer; the comparison the market draws is with other large diversified drug makers such as Merck.
Why Closelooknet tracks it
Pfizer carries a seat in the S&P 500 but no Closelooknet score. The diary's Daily Pulse has grouped it among the defensive names its pattern scanner watches for support, most recently tagged with a caution rather than stress regime.
What the diary watches
Whether Pfizer keeps printing the caution regime the pattern scanner has assigned it, or shifts alongside the other defensive names it has been grouped with when broader risk sentiment moves.

Pfizer Inc (PFE) trades on US exchanges.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: PFE news on the tape · index compare · sector dispersion · scanner.

The Street on this name 3 analyst actions on the wire · latest: price target by Freedom Broker, 2026-11-06

The Street on this name

Analyst actions and the latest print for PFE from the Closelooknet wires — third-party opinions on the record, not our readings.

  • Price target Freedom Broker — target 34 Target set to $34 (+16% to spot) 2026-11-06
  • Price target Argus — target 40 Target set to $40 (+29.9% to spot) 2026-11-04
  • Price target Scotiabank — target 33 from 30 Target raised to $33 from $30 (+20.9% to spot) 2026-10-06

3 actions on the analyst wire since 2026-08-13: 3 target changes. Analyst wire → · Earnings wire →

Dividends and capital return trailing yield 7.32%, quarterly · last 0.43 USD on 2026-11-06

Dividends and capital return

What PFE pays out and buys back — distributions read from the price series, money terms from the filings.

  • Trailing 12 months 2.15 USD per share · a 7.32% yield on the 2026-11-06 close 5 distributions, paid quarterly 2026-11-06
  • Change on the year +25.7% against the prior twelve months prior twelve months 1.71 USD per share
  • Last distribution 0.43 USD per share as the price series records it, within days of the ex-date 2026-11-06
  • By calendar year 2023: 0.41 USD (partial) · 2024: 1.68 USD · 2025: 1.72 USD · 2026: 1.72 USD to date first distribution recorded in the three-year window: 2023-11-09

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

FAQ · from the current data · as of 2026-11-07

Quick answers

What is Pfizer Inc (PFE)?

Pfizer Inc trades as PFE on the US exchange (US) in the Closelooknet research universe, as of the registry build of 2026-11-07.

Is PFE in a Closelooknet index?

Not currently — Pfizer Inc is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-11-07.

Where does PFE trade against its moving averages?

Pfizer Inc trades 2.5% above its 50-day and 9.4% above its 200-day moving average (0.6% below its 20-day). As of 2026-11-06 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does Pfizer Inc compare with its peers?

Against its peer group (Drug Manufacturers - General · US), Pfizer Inc (PFE) sits 5.2% below its 52-week high, 2.5% above its 50-day average; Amgen Inc (AMGN) is 4.9% below, GSK plc (GSK) is 16.3% below, Sanofi ADR (SNY) is 5.8% below, as of 2026-11-06. Put any of them next to PFE in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

How does Pfizer Inc trade when bond yields rise?

Over the past year Pfizer Inc had a beta of 0.53 to TLT, the long-dated Treasury fund — it tends to move with bonds, higher than 45% of US names. On the 10 sessions in which long bonds fell most it moved −0.54% on average, against −0.74% for the S&P 500. As of 2026-11-06; The "How it trades on rate days" block on this page carries the lines.

Where has Closelooknet written about Pfizer Inc?

Pfizer Inc appears in 7 Closelooknet pieces as of 2026-11-07, most recently Daily Pulse: Rubin surges as vol complex splits and Europe extends gains (2026-05-22); Daily Pulse: Layer-1 chips surge as Europe and US futures fade (2026-05-21); Daily Pulse: Narrow tape: Rubin leads as broad market softens across asset classes (2026-05-20). What Closelooknet said most recently: The reading sits just above the neutral midpoint, consistent with a market that has bounced but not yet committed to a sustained risk-on regime. §11 — Pattern Scanner Active 28 signals · PFE 36 🟡 support-confluence · MCD 36 🟡… (Daily Pulse, 2026-05-21). The "Mentioned on Closelooknet" block on this page lists the long reads, the reference entries and the dailies that name it.

What does Pfizer Inc do?

Pfizer discovers, develops, manufactures and sells biopharmaceutical products worldwide, organised into three segments: Biopharma, PC1 and Pfizer Ignite. Its brands cover internal medicine such as Eliquis and Nurtec, vaccines such as Prevnar and Abrysvo, inflammation and immunology treatments such as Xeljanz and Enbrel, rare disease medicines such as Vyndaqel, oncology therapies such as Ibrance and Xtandi, and biosimilars and sterile injectables. It is headquartered in New York and has traded publicly since 1942. The diary records no formal peer group for Pfizer; the comparison the market draws is with other large diversified drug makers such as Merck. (Company snapshot of 2026-09-17.)

Where does Pfizer Inc sit in the AI build-out?

Pfizer holds no seat in Rubin, the diary's AI build-out index, and sits outside that stack. In our wider universe it belongs to the healthcare sleeve, under drug manufacturing, alongside other large diversified pharmaceutical companies. Pfizer carries a seat in the S&P 500 but no Closelooknet score. The diary's Daily Pulse has grouped it among the defensive names its pattern scanner watches for support, most recently tagged with a caution rather than stress regime. (Company snapshot of 2026-09-17.)

Does Pfizer Inc pay a dividend?

Pfizer Inc has paid 2.15 USD per share over the last twelve months, paid quarterly, a trailing yield of 7.32% on the 2026-11-06 close; the last distribution recorded in the price series was 0.43 USD on 2026-11-06. As of 2026-11-06; the "Dividends and capital return" block on this page carries the lines.

What has Wall Street done on Pfizer Inc recently?

The most recent analyst action on Pfizer Inc on the Closelooknet wire is a price target by Freedom Broker on 2026-11-06 (target 34). 3 actions on the analyst wire since 2026-08-13: 3 target changes. Analyst actions are third-party opinions recorded by the wire, not Closelooknet readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for PFE, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

How to use this chart

Toolbar

  • Range — 1M to MAX on daily closes. 1D/5D switch a US stock cell to 5-minute intraday bars; index and foreign cells fall back to 1M daily with a note.
  • Grid — 1×1 up to 2×2. Cells are synchronized: pan or zoom one and the others follow the same dates; the crosshair tracks across all of them. 4 INDICES loads Rubin · HALO · AEI · AW40 side by side.
  • Type / Scale — OHLC, line or area; linear or log price axis.

Picking a series

  • Tap the box in a cell's header to browse every Closelooknet series — headline indices, sub-indices, sectors, layers of all six families — plus the constituents.
  • Or type any ticker (NVDA, 7203.T, ASML.AS …) and press Enter — it charts in the cell straight from our data lake.

Studies

  • Overlays / Oscillators rows toggle the standard set (SMA, Bollinger, RSI, MACD …) per cell.
  • Levels (stock cells) draws the structure engine's support lines — regression bands, pivot cluster, SMA-200, the active fib zone.

Drawing

  • Tap a tool (Trend, Ray, H-Line, Fib, Channel, Rect, Note), then tap the chart once per point — the shape follows your finger or cursor between taps. The chart stops panning while a tool is armed; tap the tool again to release.
  • Drawings save per symbol in this browser and travel between the terminal and the asset page.
  • Delete key removes the selected drawing · Escape cancels a half-placed one · Clear wipes the symbol.

Wave counts

  • Wave places an Elliott count: tap the origin, then each wave end. Press Enter to stop early (inside wave 3 is fine) — dotted ghost targets sketch the remaining waves at guideline ratios.
  • On stocks the scanner's machine count appears automatically in grey — it is fully editable: drag any point, double-tap a label to remove it, Delete to dismiss it for good, Adopt to bring the machine's proposal back.
  • The sequence picker switches 1-5 / A-B-C / A-E / W-X-Y-Z; 1 2 3 cycles the degree; Subdiv starts a one-degree-smaller child count inside a wave.

Sharing

  • Card exports the cell as a branded PNG — chart, drawings and levels exactly as shown.

Related in the Closelooknet universe

then Drug Manufacturers - General. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.